# OnCo record nct04099251 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04099251/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04099251", "NCT04099251" ;
  schema:name "Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma"@en ;
  schema:alternateName "CheckMate 76K"@en ;
  schema:description "A phase 3 trial of Nivolumab in melanoma, run by Bristol-Myers Squibb, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04099251/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04099251> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2019-10-28" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/stage-ii-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-checkmate-76k-nat-med-2023/> .